You can buy or sell SELB and other stocks, options, and ETFs commission-free!
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA. The listed name for SELB is Selecta Biosciences, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 11, Pre-Market